NASDAQ:MNLO - Menlo Therapeutics Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $5.57 +0.05 (+0.91 %) (As of 01/21/2019 03:25 AM ET)Previous Close$5.57Today's Range$5.49 - $5.7152-Week Range$3.74 - $39.86Volume99,161 shsAverage Volume147,320 shsMarket Capitalization$129.40 millionP/E Ratio-0.98Dividend YieldN/ABetaN/A ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Menlo Therapeutics Inc., a late-stage biopharmaceutical company, focuses on the development and commercialization of serlopitant for the treatment of pruritus associated with dermatologic conditions in the United States. The company has completed Phase II clinical trials in pruritus associated with prurigo nodularis. It is also developing products that are in Phase II clinical trials to treat pruritus associated with psoriasis, atopic dermatitis, and refractory chronic cough. The company was formerly known as Tigercat Pharma, Inc. and changed its name to Menlo Therapeutics Inc. in May 2016. Menlo Therapeutics Inc. was founded in 2011 and is headquartered in Redwood City, California. Receive MNLO News and Ratings via Email Sign-up to receive the latest news and ratings for MNLO and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:MNLO Previous Symbol CUSIPN/A Webwww.menlotherapeutics.com Phone650-486-1416Debt Debt-to-Equity RatioN/A Current Ratio19.16 Quick Ratio19.16Price-To-Earnings Trailing P/E Ratio-0.98 Forward P/E Ratio-2.25 P/E GrowthN/A Sales & Book Value Annual Sales$4.58 million Price / Sales28.25 Cash FlowN/A Price / Cash FlowN/A Book Value($2.60) per share Price / Book-2.14Profitability EPS (Most Recent Fiscal Year)($5.69) Net Income$-29,070,000.00 Net Margins-268.61% Return on Equity-41.70% Return on Assets-30.31%Miscellaneous Employees32 Outstanding Shares23,230,000Market Cap$129.40 million OptionableNot Optionable Menlo Therapeutics (NASDAQ:MNLO) Frequently Asked Questions What is Menlo Therapeutics' stock symbol? Menlo Therapeutics trades on the NASDAQ under the ticker symbol "MNLO." How were Menlo Therapeutics' earnings last quarter? Menlo Therapeutics Inc (NASDAQ:MNLO) released its quarterly earnings data on Wednesday, November, 7th. The company reported ($0.56) earnings per share for the quarter, beating the consensus estimate of ($0.89) by $0.33. Menlo Therapeutics had a negative return on equity of 41.70% and a negative net margin of 268.61%. View Menlo Therapeutics' Earnings History. When is Menlo Therapeutics' next earnings date? Menlo Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, March 27th 2019. View Earnings Estimates for Menlo Therapeutics. What price target have analysts set for MNLO? 7 analysts have issued 12-month price targets for Menlo Therapeutics' stock. Their predictions range from $7.00 to $48.00. On average, they anticipate Menlo Therapeutics' stock price to reach $27.3333 in the next twelve months. This suggests a possible upside of 390.7% from the stock's current price. View Analyst Price Targets for Menlo Therapeutics. What is the consensus analysts' recommendation for Menlo Therapeutics? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Menlo Therapeutics in the last year. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Menlo Therapeutics. What are Wall Street analysts saying about Menlo Therapeutics stock? Here are some recent quotes from research analysts about Menlo Therapeutics stock: 1. According to Zacks Investment Research, "Menlo Therapeutics Inc. is a late stage biopharmaceutical company. It focused on the development of serlopitant and treatment of chronic itch and chronic refractory cough. The company's product pipeline consists of Prurigo Nodularis Itch, Atopic Dermatitis Itch, Psoriasis Itch and Refractory Chronic Cough which are in clinical stage. Menlo Therapeutics Inc. is headquartered in Redwood City, California. " (1/18/2019) 2. Cantor Fitzgerald analysts commented, ". After a solid quarter of execution in 3Q18, we reiterate our OW rating and 12-month price target of $25 for MNLO shares. We continue to believe that upward earnings revisions and multiple expansion will drive the stock higher. A greater appreciation for the company’s multiple indication approach for serlopitant will increase earnings estimates to levels not yet reflected in consensus expectations, in our view." (11/7/2018) Has Menlo Therapeutics been receiving favorable news coverage? Media coverage about MNLO stock has been trending somewhat negative on Monday, according to InfoTrie Sentiment. The research firm scores the sentiment of media coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Menlo Therapeutics earned a news sentiment score of -1.4 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the near term. Who are some of Menlo Therapeutics' key competitors? Some companies that are related to Menlo Therapeutics include NuCana (NCNA), Zymeworks (ZYME), Obseva (OBSV), BioSpecifics Technologies (BSTC), Theratechnologies (THERF), Prothena (PRTA), Innate Pharma (IPHYF), GlycoMimetics (GLYC), Eidos Therapeutics (EIDX), Corium International (CORI), ZEALAND PHARMA/S (ZEAL), Odonate Therapeutics (ODT), Akorn (AKRX), Forty Seven (FTSV) and Arcus Biosciences (RCUS). Who are Menlo Therapeutics' key executives? Menlo Therapeutics' management team includes the folowing people: Mr. Steven L. Basta, Pres, CEO & Director (Age 53)Ms. Kristine M. Ball CPA, Sr. VP of Corp. Strategy & CFO (Age 47)Dr. Paul S. Kwon M.D., Chief Scientific Officer (Age 48)Mr. Stuart D. Sedlack M.B.A., VP of Bus. Devel. (Age 54)Dr. Xiaoming Zhang Ph.D., Sr. VP of Non-Clinical & Pharmaceutical Devel. (Age 55) When did Menlo Therapeutics IPO? (MNLO) raised $86 million in an initial public offering (IPO) on Thursday, January 25th 2018. The company issued 5,700,000 shares at $14.00-$16.00 per share. Jefferies, Piper Jaffray and Guggenheim Securities served as the underwriters for the IPO and JMP Securities was co-manager. How do I buy shares of Menlo Therapeutics? Shares of MNLO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Menlo Therapeutics' stock price today? One share of MNLO stock can currently be purchased for approximately $5.57. How big of a company is Menlo Therapeutics? Menlo Therapeutics has a market capitalization of $129.40 million and generates $4.58 million in revenue each year. The company earns $-29,070,000.00 in net income (profit) each year or ($5.69) on an earnings per share basis. Menlo Therapeutics employs 32 workers across the globe. What is Menlo Therapeutics' official website? The official website for Menlo Therapeutics is http://www.menlotherapeutics.com. How can I contact Menlo Therapeutics? Menlo Therapeutics' mailing address is 200 CARDINAL WAY 2ND FLOOR, REDWOOD CITY CA, 94063. The company can be reached via phone at 650-486-1416 or via email at [email protected] MarketBeat Community Rating for Menlo Therapeutics (NASDAQ MNLO)Community Ranking: 2.1 out of 5 ( )Outperform Votes: 54 (Vote Outperform)Underperform Votes: 75 (Vote Underperform)Total Votes: 129MarketBeat's community ratings are surveys of what our community members think about Menlo Therapeutics and other stocks. Vote "Outperform" if you believe MNLO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MNLO will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 1/21/2019 by MarketBeat.com StaffFeatured Article: What is the LIBOR?